BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35412868)

  • 1. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
    Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
    Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 4. ThyroSeq
    Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
    Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
    Hall EA; Hartzband P; VanderLaan PA; Nishino M
    Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 11. The utility of ThyroSeq
    Li W; Justice-Clark T; Cohen MB
    Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
    Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ
    Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
    Selvaggi SM
    Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
    Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
    Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
    O'Conor CJ; Dash RC; Jones CK; Jiang XS
    Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Lobectomy for Bethesda III Thyroid Nodules: Pathological Outcomes and Risk Factors for Malignancy.
    Walters BK; Garrett SL; Aden JK; Williams GM; Butler-Garcia SL; Newberry TR; Mckinlay AJ
    Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1064-1068. PubMed ID: 33567896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.